ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / IKT / financials
PLX (23) ARTV (27) PALI (32) OCGN (25) ⌘ Pro Terminal →

Inhibikase Therapeutics Inc. (IKT) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$1.54 -0.64% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.54

Inhibikase Therapeutics Inc. (IKT) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $216.3M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on IKT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is IKT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Inhibikase Therapeutics Inc. (NASDAQ: IKT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $1.54 (-0.64% 1D, market cap $216.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, IKT ranks #832 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does IKT compare to PLX and ARTV in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IKT carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PLX (Protalix BioTherapeutics Inc.) holds a E grade (23/100 RQD, P/E N/A, ROIC -13.0%, cap $208.7M) and ARTV (Artiva Biotherapeutics Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $204.8M). Among the 5-stock peer group, IKT leads on earnings multiple (N/A) while PLX leads on capital efficiency (-13.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for IKT?
▼

Per IKT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001750149), Inhibikase Therapeutics Inc. generated $145.5M in revenue (+81.8% YoY), -$48.3M in net income, and -$27.8M in free cash flow against $181.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.54 (-0.31%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510029
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (8)Whales (3)SEC (10)Macro (5)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-13% Base Target
$3 Bull$1 Base$1 Bear
📬 FREE IKT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IKT)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (29/100 Composite)
🔍 WHY IKT SCORES 29/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (34% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (28% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
37
Grade E$1.85-11.4% Next Q
Q2 (-2Q)
34
Grade E$1.64-7.3% Next Q
Q3 (-1Q)
32
Grade E$1.52+1.3% Next Q
Current
29
Grade E$1.54-9.8% Hist 90D α
Trajectory: E (37) → E (29)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a IKT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While IKT currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.06) and Max Pain ($1.62) forces dealer call-delta covering toward $2.74.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IKT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “IKT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 29%NO 71%Trade / Inspect Odds →
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How IKT Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)
Revenue$145.5MGross Profit $75.7M (52%)Cost of Sales $69.9MOp Profit $0 (0%)OpEx (R&D/SG&A) $75.7MNet Profit$0 (0%)Tax/Other $0

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow
FY23
Rev $260.5K
FY24
Rev $80.0M
FY25
Rev $145.5M
Fiscal YearRevenueGross MarginOp MarginNet ProfitFree Cash FlowROIC %
FY 2025$145.5M52%-35.7%-$48.3M-$27.8M-45%
FY 2024$80.0M52%-35.7%-$27.5M-$19.1M-45%
FY 2023$260.5K52%-80%-$19.0M-$18.1M-35%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IKT)

  • ✓Walkthrough of IKT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
IKT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -20.62%🛡️ HOLDING TREND SUPPORT
2026-11-03O $1.67H $1.67L $1.54C $1.54VOL 438.3K
RES: $2.72SUP: $1.48SMA50: $2.06SMA200: $1.94
$2.69$2.37$2.04$1.72$1.40RES $2.72SUP $1.48$1.542026-05-042026-06-172026-08-042026-09-172026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IKT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IKT Butterfly Map → + Track IKT →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +81.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on IKT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IKT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IKT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IKT)

Health Care Rank #832 of 1015 ⚔️ PLX vs IKT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IKT vs. PLX, ARTV, PALI, OCGN)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Inhibikase Therapeutics Inc. (IKT) ranks #832 by composite RQD confidence (29/100, grade E) and #563 by equity capitalization ($216.3M). Within this direct 5-issuer industry benchmark cohort, IKT leads on earnings valuation at N/A trailing P/E, while PLX leads on capital efficiency and profitability with -13.0% ROIC and 48.8% gross margin. PALI currently holds the highest overall quantitative score in the immediate peer group at 32/100 (E) compared with IKT at 29/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
IKT ACTIVE
Inhibikase Therapeutics Inc.
E 29/100 — — -35.0% -0.64% $216.3M Benchmark Subject
PLX
Protalix BioTherapeutics Inc.
E 23/100 — 48.8% -13.0% -1.16% $208.7M /plx-vs-ikt →
ARTV
Artiva Biotherapeutics Inc.
E 27/100 — — -35.0% 0.00% $204.8M /artv-vs-ikt →
PALI
Palisade Bio Inc.
E 32/100 — — -35.0% -3.45% $202.2M /pali-vs-ikt →
OCGN
Ocugen Inc.
E 25/100 — — -35.0% +3.13% $238.3M /ocgn-vs-ikt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001750149 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Inhibikase Therapeutics Inc. (IKT) reported GAAP revenue of $145.5M (+81.8% vs. FY2024 revenue of $80.0M , and +55764.7% cumulative change since FY2023) , GAAP net income of -$48.3M, operating cash flow of -$27.8M, and free cash flow of -$27.8M (-45.2% YoY). On the balance sheet, IKT closed FY2025 with $181.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $145.5M -$48.3M -$27.8M -$27.8M $181.2M —
FY2024 (FY) 2024-12-31 $80.0M -$27.5M -$19.1M -$19.1M $98.6M —
FY2023 (FY) 2023-12-31 $260.5K -$19.0M -$18.1M -$18.1M — —

3. IKT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IKT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Inhibikase Therapeutics Inc. (NASDAQ: IKT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $1.54 (-0.64% 1D, market cap $216.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, IKT ranks #832 in composite RQD confidence.

How does IKT compare to PLX and ARTV in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IKT carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PLX (Protalix BioTherapeutics Inc.) holds a E grade (23/100 RQD, P/E N/A, ROIC -13.0%, cap $208.7M) and ARTV (Artiva Biotherapeutics Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $204.8M). Among the 5-stock peer group, IKT leads on earnings multiple (N/A) while PLX leads on capital efficiency (-13.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IKT?

Per IKT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001750149), Inhibikase Therapeutics Inc. generated $145.5M in revenue (+81.8% YoY), -$48.3M in net income, and -$27.8M in free cash flow against $181.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IKT trading relative to its 50-day, 200-day, and 52-week technical levels?

IKT last traded at $1.54 (-0.64% on volume of 449,236 shares), positioning the stock -25.24% below its 50-day simple moving average ($2.06) and -20.62% below its 200-day simple moving average ($1.94). Across its 52-week range of $1.33 to $2.61, IKT sits at the 16.4% percentile with a 14-day RSI of 33.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.35 to $1.73).

Direct Sub-Reports: IKT RQD Cockpit IKT 12M Forecast IKT Earnings & Move IKT Dividends & DRIP IKT Insiders & 13F IKT Whale Options IKT Profit Sankey IKT News & Why
ROARABLE RATING BRIEF • RQD 29/100 (E) ✓ SEC XBRL & RQD VERIFIED

IKT — Inhibikase Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Inhibikase Therapeutics Inc. (IKT) earns a live Roarable RQD composite score of 29/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.54 (-0.64% 1D, market capitalization $216.3M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -11.93%.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (5/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Inhibikase Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry..2B. Reported revenue is — in FY 2025 and FY 2024, with $0.3M in FY 2023.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Inhibikase Therapeutics Inc. (IKT) reported $145.5M in annual revenue (up from $80.0M in FY2024, +81.8% YoY) and -$48.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($260.5K revenue, -$19.0M net income) through FY2025, IKT scaled operating cash flow to -$27.8M and free cash flow to -$27.8M, backed by $181.2M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 29/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -11.93% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.33 – $2.61 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), IKT carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can IKT sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $145.5M and free cash flow of -$27.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is IKT's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

IKT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Inhibikase Therapeutics Inc. (IKT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to IKT Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

IKT Bull vs. Bear Conversation Board — What's Your Call at $1.54?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IKT 🐻 33% BEARISH CONVICTION
1. Pick Your Side on IKT:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $1.88 (+21.3%)
📌 Pinned Debate

Cash on hand rose to $178.8M at FY 2025 from $97.5M a year earlier, giving the company a larger buffer against its operating losses.

Cash on hand rose to $178.8M at FY 2025 from $97.5M a year earlier, giving the company a larger buffer against its operating losses.. When you look under the hood at IKT, Fundamental Cash Engine is 8/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $2.61. My 12M target is $1.88.

VolSurface_Trader 🐂 BULL

@MeanReversion_88 Shorting a 3/20 institutional whale-flow stock at $1.55 is dangerous when funds are rotating into Health Care.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $1.22 (-21.3%)
Spot @ $1.55

Operating losses widened from -$20.1M in FY 2023 to -$52.0M in FY 2025 with no reported revenue in the last two years, and FCF yield is

Fading this rally in IKT at $1.55. Operating losses widened from -$20.1M in FY 2023 to -$52.0M in FY 2025 with no reported revenue in the last two years, and FCF yield is -11.93%.. With a beta of 1.0 and the stock sitting at $1.55 (52-wk range $1.33–$2.61), the easy multiple expansion is already priced in.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%